Immunocore Holdings (IMCR) Operating Expenses (2021 - 2026)

Immunocore Holdings (IMCR) has reported Operating Expenses for 6 consecutive years, with $99.0 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses rose 2.38% year-over-year to $99.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $442.6 million (up 17.13% YoY) and the FY2025 annual result came in at $440.3 million, up 16.5% from the prior year.
• Operating Expenses retreated to $99.0 million in Q1 2026 per IMCR's latest filing, from $121.5 million in the prior quarter.
• Over the last five years, Operating Expenses for IMCR reached as high as $121.5 million in Q4 2025 and fell as low as $41.2 million in Q3 2022.
• A 5-year average of $87.8 million and a median of $89.0 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses decreased 18.88% — and 2023, when it jumped 91.03%.
• Year by year, Operating Expenses stood at $82.4 million in 2022, then climbed by 5.56% to $87.0 million in 2023, then grew by 18.57% to $103.2 million in 2024, then gained by 17.73% to $121.5 million in 2025, then dropped by 18.53% to $99.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $99.0 million, $121.5 million, and $110.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.